PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion … (NCT05493904) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)
South Korea320 participantsStarted 2022-11-01
Plain-language summary
The aim of the study is to compare post-interventional fractional flow reserve (FFR) value between optical coherence tomography(OCT)-guided and angiography-guided strategy for treatment of complex coronary lesion.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients \>18 years old
✓. Patients with stable or unstable angina and complex coronary lesions\*
✓. Patients who were indicated revascularization
✓. Patients who underwent implantation of 2nd generation drug-eluting stent
✓. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
✓. Chronic total occlusion (≥3 months) as target lesion
✓. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)
✓. Long coronary lesions (implanted stent ≥38 mm in length)
Exclusion criteria
✕. Target lesions not amenable for PCI by operators' decision
✕. Cardiogenic shock (Killip class IV) at presentation
✕. Less than TIMI 3 flow of target vessel after index procedure
✕. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Everolimus, Zotarolimus, Biolimus, or Sirolimus
✕. Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)